Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: A study with a questionnaire

The objective was to evaluate the efficacy of the information policy given to all systemic lupus erythematosus (SLE) patients. One hundred consecutive SLE patients were asked to answer anonymously a questionnaire covering demographic issues including education, adherence with prescriptions and advice given and methods of sourcing information. Seventy-three females and ten males responded. The demographic data showed that 34 had a university education, 29 high school and 19 primary school education. An inability to work due to disease was increased compared with the matched population (P < 0.001). Forty-two reported that they had received advice about physical training and forty of them followed this advice. Only 28 out of 46 smokers reported that they had got any advice about smoking, and out of these only 13 followed the advice. The patients with university background were less likely to smoke (P < 0.05) and followed the advice more often (P < 0.05). Most patients followed given advice about exposure to sunlight. Thirty-five percent of those prescribed glucocorticoids reported that they varied from the prescribed dosages without consultation with their specialist. This behaviour was more common in the university group (P < 0.05), this grouping also had a higher median dosage. Seventy-three patients had read the booklet about SLE provided by the clinic. Accessing internet information was more common for those with university education (P < 0.01). This study shows that on the whole SLE patients follow given advice, but adherence varies. Aside from the issue of glucocorticoid dosage adherence, educational level seems to be the most important predictor for adherence to advice. Thus, we conclude that a more individualized approach to delivery of information is required and better follow up is needed. Lupus (2007) 16, 701—706.

[1]  W. Kannel,et al.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.

[2]  M. Liang,et al.  Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[3]  P. Sloane,et al.  Patients' perceptions of primary care physicians' participatory decision-making style and communication about complementary and alternative medicine for arthritis. , 2005, Journal of alternative and complementary medicine.

[4]  J. Frostegård,et al.  SLE, atherosclerosis and cardiovascular disease , 2005, Journal of internal medicine.

[5]  M. Suarez‐Almazor,et al.  Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. , 2005, The Journal of rheumatology.

[6]  H. Zeidler,et al.  Employment across chronic inflammatory rheumatic diseases and comparison with the general population. , 2005, The Journal of rheumatology.

[7]  A. Boonen Everyone has the right to work. , 2005, The Journal of rheumatology.

[8]  A. Hingorani,et al.  Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. , 2004, Rheumatology.

[9]  F. Granath,et al.  Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. , 2004, The Journal of rheumatology.

[10]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[11]  I. Bruce,et al.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. , 2003, Arthritis and rheumatism.

[12]  M. Ward,et al.  Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus , 2003, Lupus.

[13]  O. Nived,et al.  Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. , 2002, Rheumatology.

[14]  K. Asplund,et al.  Use of complementary and alternative medicine remedies in Sweden. A population‐based longitudinal study within the northern Sweden MONICA Project , 2001, Journal of internal medicine.

[15]  M. Ward,et al.  Mortality and causes of death in systemic lupus erythematosus , 2001, Current opinion in rheumatology.

[16]  Y. Brandberg,et al.  Beliefs, knowledge and attitudes as predictors of sunbathing habits and use of sun protection among Swedish adolescents , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[18]  C. Aranow,et al.  Epidemiology of cardiovascular disease in systemic lupus erythematosus , 2000, Lupus.

[19]  L. Vilá,et al.  Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. , 1999, Puerto Rico health sciences journal.

[20]  I. Bruce,et al.  The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.

[21]  D. Gladman,et al.  Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. , 1998, The Journal of rheumatology.

[22]  T. Davis,et al.  Literacy in patients with a chronic disease: systemic lupus erythematosus and the reading level of patient education materials. , 1997, The Journal of rheumatology.

[23]  M. Liang,et al.  Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. , 1997, Arthritis and rheumatism.

[24]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. , 1997, The Journal of rheumatology.

[25]  L. Hy,et al.  Prednisolone non-compliance and its related factors in patients with systemic lupus erythematosus. , 1995 .

[26]  M. Petri,et al.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.

[27]  D. Isenberg,et al.  Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.

[28]  D. Wallace,et al.  Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. , 1990, The American journal of medicine.

[29]  M. Hochberg,et al.  Systemic lupus erythematosus. , 1990, Rheumatic diseases clinics of North America.

[30]  A. Silman,et al.  Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. , 1990, British journal of rheumatology.

[31]  M. Urowitz,et al.  The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.

[32]  J. Deckers,et al.  Smoking behaviour in European patients with established coronary heart disease. , 2006, European heart journal.

[33]  D. Upchurch,et al.  Use of complementary and alternative medicine among American women. , 2005, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[34]  J Thumboo,et al.  Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. , 1999, Arthritis and rheumatism.

[35]  O. Nived,et al.  Epidemiology of systemic lupus erythematosus. , 1987, Monographs in allergy.

[36]  J. Paterson Serum Lipoproteins and Coronary Artery Disease. , 1957, Canadian Medical Association journal.